Riesgos de trombosis venosa profunda, embolia pulmonar y sangrado postcovid-19

Paula Villares Fernández

Paula Villares Fernández Medicina Interna. Hospital Universitario HM Sanchinarro, Madrid.

Palabras clave: Trombosis venosa profunda, Tromboembolia pulmonar, Hemorragia, COVID-19

Abstract

La enfermedad por SARS Cov2 es un factor de riesgo de infarto de miocardio y accidente cerebrovascular. Las publicaciones sobre complicaciones cardiovasculares han ido en aumento.

Resulta muy importante poder cuantificar el riesgo de trombosis venosa profunda, embolismo pulmonar y sangrado después de haber padecido COVID-19.

Recibido: 03 Octubre 2022
Revisión: 10 Octubre 2022
Aceptado: 14 Octubre 2022

Citas

Vol 271 Nº6; págs. 608-618. 2012. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sørensen HT. Acute infections and venous thromboembolism. Journal of International Medicine. DOI: https://doi.org/10.1111/j.1365-2796.2011.02473.x

Vol 9 Nº1. 2014. Dalager-Pedersen, Michael et al. “Venous thromboembolism after community-acquired bacteraemia: a 20-year danish cohort study.” PLOS ONE. DOI: http://doi.org/10.1371/journal.pone.0086094.

Vol 275 Nº4; págs. 387-397. 2014. Mejer, N et al. “Increased risk of venous thromboembolism within the first year after Staphylococcus aureus bacteraemia: a nationwide observational matched cohort study.” Journal of internal medicine. DOI: https://doi.org/10.1111/joim.12147

Vol 376 Nº18; págs. 2060-2072. 2020. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, Morrison RB, Leiva O, Fanikos J, Nauffal V, Almarzooq Z, Goldhaber SZ. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Journal of The American College of Cardiology. DOI: https://doi.org/10.1016/j.jacc.2020.08.070

Vol 395 Nº10234; págs. 1417-1417. 2020. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30937-5

Vol 9 Nº11; págs. 2508. 2020. Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells. DOI: https://doi.org/10.3390/cells9112508

Vol 2 Nº7; págs. 437-445. 2020. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. DOI: https://doi.org/10.1016/S2665-9913(20)30121-1

Vol 201; págs. 23-29. 2021. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thrombosis Research. DOI: https://doi.org/10.1016/j.thromres.2021.02.010

Vol 11 Nº1022. 2020. Liang, Yanwen et al. “Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.” Frontiers in immunology vol. 11 1022. 12 May. 2020. DOI: https://doi.org/10.3389/fimmu.2020.01022

Vol 374 Nº1931. 2021. Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARSCoV-2 positive testing: self-controlled case series study. BMJ. DOI: https://doi.org/10.1136/bmj.n1931

Vol 96 Nº10; págs. 2587-2597. 2021. Ho FK, Man KKC, Toshner M, et al. Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A SelfControlled Case Series Analysis of a Nationwide Cohort. Mayo Clinic Proceedings. DOI: https://doi.org/10.1016/j.mayocp.2021.07.002

Vol 181 Nº12; págs. 1612-1620. 2021. Spyropoulos AC, Goldin M, Giannis D, et al, HEP-COVID Investigators. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Internal Medicine.

Vol 181 Nº12; págs. 1621-1622. 2021. Wahid L, Ortel TL. Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Internal Medicine. DOI: http://doi.org/10.1001/jamainternmed.2021.6212